Non-small cell lung cancer patients who are ineligible for platinum-based chemotherapy benefit from atezolizumab monotherapy.

Published Date: 16 Aug 2023

First-line atezolizumab monotherapy is linked to improved overall survival compared to single-agent chemotherapy in patients with non-small cell lung cancer (NSCLC) who are ineligible for platinum-based chemotherapy.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Herpes virus-based vaccine shows promise in targeting tumors without side effects

2.

Characterizing metastatic disease during adaptive therapy by using dynamic biomarkers and mathematical modeling.

3.

a brand-new generic therapy for different types of cancer.

4.

Survey shows cancer anxiety has impact well beyond the individual diagnosed

5.

If CD19 CAR T-Cell Therapy Fails in Lymphoma, Try a CD22 Version


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot